id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S3471 R11257 |
Bérard, 2019 | Major malformations | 1st trimester | population based cohort propective | unexposed (general population or NOS) | Adjustment: Yes | 0.57 [0.13;2.49] | 2/31 14,402/179,106 | 14,404 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3852 R11260 |
Huybrechts, 2019 | Congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Intravenous | 1.02 [0.96;1.08] | -/23,866 -/1,762,018 | - | 23,866 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2852 R11261 |
Huybrechts (Control exposed to other treatment), 2018 | Any congenital malformations | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.00 [0.95;1.05] excluded (control group) |
2,067/55,579 6,137/185,699 | 8,204 | 55,579 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2844 R11262 |
Huybrechts (Unexposed control), 2018 | Any congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.01 [0.98;1.05] | 3,275/88,446 54,163/1,727,546 | 57,438 | 88,446 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2778 R3782 |
Fejzo (Mainly exposed to other treatements, sick), 2016 | Birth Defects (major and minor) | 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.02 [0.55;1.90] C excluded (control group) |
33/952 15/441 | 48 | 952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2776 R3744 |
Fejzo (Unexposed control, disease free), 2016 | Birth Defects (major and minor) | 1st trimester | retrospective cohort | unexposed, disease free | Adjustment: No | 1.89 [1.11;3.22] C | 33/952 24/1,286 | 57 | 952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2856 R3995 |
Shahraki, 2016 | Congenital anomaly | during pregnancy (anytime or not specified) excluded | randomized controlled trial | exposed to other treatment, sick | Adjustment: Randomisation |
1.14 [0.02;57.92] C excluded (exposition period) |
0/88 0/100 | 0 | 88 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2752 R3659 |
Danielsson, 2014 | Any malformation | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 0.95 [0.72;1.26] | 49/1,349 64,215/1,501,434 | 64,264 | 1,349 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3184 R5102 |
Ozdemirci, 2014 | Fetal anomaly | 1st trimester | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.20 [0.02;1.87] C | 1/100 4/85 | 5 | 100 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2753 R11255 |
Andersen, 2013 | Major congenital malformations | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.30 [1.00;1.70] | 58/1,248 31,357/895,770 | 31,415 | 1,248 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2775 R3722 |
Colvin, 2013 | Any birth defect | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No |
1.30 [0.80;2.10] excluded (exposition period) |
16/263 4,749/98,062 | 4,765 | 263 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2755 R11258 |
Einarson (Control exposed to other antiemetics), 2004 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.93 [0.47;7.84] C excluded (control group) |
6/169 3/160 | 9 | 169 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2754 R11259 |
Einarson (Unexposed control), 2004 | Major malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.95 [0.48;7.94] C | 6/169 3/162 | 9 | 169 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 8 studies | 1.04 [0.96;1.12] | 167,592 | 116,161 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Unexposed control; 2: Unexposed control, disease free; 3: Unexposed control;
Asymetry test p-value = 0.5341 (by Egger's regression)
slope=0.0065 (0.0257); intercept=0.4000 (0.6066); t=0.6594; p=0.5341
excluded 2755, 2778, 2852